Differential regulation of Noxa in normal melanocytes and melanoma cells by proteasome inhibition: Therapeutic implications

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6294-6304

  Fernández, Yolanda ^a   Verhaegen, Monique ^a   Miller, Thomas P ^a   Rush, Jenny L ^a   Steiner, Philipp ^b,d   Opipari Jr , Anthony W ^a   Lowe, Scott W ^c   Soengas, María S ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BORTEZOMIB; CELL PROTEIN; DOXORUBICIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN NOXA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; PRIORITY JOURNAL; RNA INTERFERENCE; SKIN CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CASPASES; CISPLATIN; CYTOCHROMES C; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; HUMANS; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RNA INTERFERENCE; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22244454745     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0686     Document Type: Article

References (47)

1. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001;20:3-11.
2. Houghton AN, Polsky D. Focus on melanoma. Cancer Cell 2002;2:275-8.
3. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003;22:3152-61.
4. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
5. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21-34.
6. Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 2003;4:2205-11.
7. Lawson DH. Update on the systemic treatment of malignant melanoma. Semin Oncol 2004;31:33-7.
8. Garber K. Cancer research. Taking garbage in, tossing cancer out? Science 2002;295:612-3.
9. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
10. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
11. Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-64.
12. Goy A, Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin Lymphoma 2004;4:230-7.
13. Lenz HJ. Clinical update: proteasome inhihitors in solid tumors. Cancer Treat Rev 2003;29:41-8.
14. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004;64:4912-8.
15. Poetsch M, Dittberner T, Woenckhaus C. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet Cytogcnet 2001;125:21-6.
16. Yu J, Tiwari S, Steiner P, Zhang L. Differential apoptotic response to the proteasome inhibitor bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther 2003;2:694-9.
17. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003;113:88-95.
18. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
19. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-κ activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88-95.
20. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719-28.
21. Satherlcy K, de Souza L, Neale MH, et al. Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma. J Pathol 2000;192:174-81.
22. Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-10.
23. Satyamoorthy K, Meier F, Hsu MY, Berking C, Herlyn M. Human xenografts, human skin and skin reconstructs for studies in melanoma development and progression. Cancer Metastasis Rev 1999;18:401-5.
24. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.
25. McCurrach ME, Lowe SW. Methods for studying pro-and antiapoptotic genes in nonimmortal cells. Methods Cell Biol 2001;66:197-227.
26. Wilkinson JC, Cepero E, Boise LH, Duckett CS. Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol Cell Biol 2004;24:7003-14.
27. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002;295:868-72.
28. Satyamoorthy K, DeJesus E, Linnenbach AJ, et al. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997;7:535-42.
29. Ahmann DL, Bisel HF, Edmonson JH, et al. Clinical comparison of Adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma. Clin Pharmacol Ther 1976;19:821-4.
30. Ridolli R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon α-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:1600-7.
31. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
32. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-9.
33. Nijhawan D, Fang M, Traer E, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003;17:1475-86.
34. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403.
35. Pavey S, Johansson P, Packer L. et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-7.
36. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8.
37. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-8.
38. Seo YW, Shin JN, Ko KH, et al. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J Biol Chem 2003;278:48292-9.
39. Qin JZ, Stennett L, Bacon P, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004;3:895-902.
40. Zheng B, Georgakis GV, Li Y, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004;10:3207-15.
41. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11-7.
42. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IκB:NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002;21:6510-9.
43. Dai DL, Martinka M, Bush JA, Li G. Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer 2004;91:1089-95.
44. Svingen PA, Loegering D, Rodriquez J, et al. Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. Clin Cancer Res 2004;10:6807-20.
45. Zanon M, Piris A, Bersani I, et al. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004;64:7386-94.
46. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15.
47. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.